表观遗传学改变的转化应用：以卵巢癌为模型。
Translational application of epigenetic alterations: ovarian cancer as a model.
机构信息
SPORE in Ovarian Cancer Program, Fox Chase Cancer Center, Philadelphia, USA.
出版信息
FEBS Lett. 2011 Jul 7;585(13):2112-20. doi: 10.1016/j.febslet.2011.03.016. Epub 2011 Mar 12.
Abstract
Cancer is a disease initiated and driven by the accumulation and interplay of genetic and epigenetic mutations of genes involved in the regulation of cell growth and signaling. Dysregulation of these genes and pathways in a cell leads to a growth advantage and clonal expansion. The epigenetic alterations involved in the initiation and progression of cancer are DNA methylation and histone modifications which interact to remodel chromatin, as well as RNA interference. These alterations can be used as candidate targets in molecular tests for risk, early detection, prognosis, prediction of response to therapy, and monitoring, as well as new therapeutic targets in cancer. In this review, we discuss the rationale, studies to date, and issues in the translational application of epigenetics using epithelial ovarian cancer as a specific example of all types of cancer.
摘要
癌症是一种由涉及细胞生长和信号转导调控的基因的遗传和表观遗传突变的积累和相互作用引发和驱动的疾病。这些基因和通路在细胞中的失调导致生长优势和克隆扩增。在癌症的发生和发展中涉及的表观遗传改变是 DNA 甲基化和组蛋白修饰，它们相互作用重塑染色质，以及 RNA 干扰。这些改变可以作为分子测试中风险、早期检测、预后、治疗反应预测和监测的候选靶点，以及癌症的新治疗靶点。在这篇综述中，我们讨论了使用上皮性卵巢癌作为所有类型癌症的具体示例的基于表观遗传学的分子测试的转化应用的原理、迄今为止的研究以及问题。
相似文献
1
Translational application of epigenetic alterations: ovarian cancer as a model.表观遗传学改变的转化应用：以卵巢癌为模型。
FEBS Lett. 2011 Jul 7;585(13):2112-20. doi: 10.1016/j.febslet.2011.03.016. Epub 2011 Mar 12.
2
Epigenetics in ovarian cancer.卵巢癌中的表观遗传学
Methods Mol Biol. 2012;863:253-69. doi: 10.1007/978-1-61779-612-8_15.
3
Minireview: epigenetic changes in ovarian cancer.综述：卵巢癌中的表观遗传变化
Endocrinology. 2009 Sep;150(9):4003-11. doi: 10.1210/en.2009-0404. Epub 2009 Jul 2.
4
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells.CD133的表观遗传调控与CD133+卵巢癌细胞的致瘤性
Oncogene. 2009 Jan 15;28(2):209-18. doi: 10.1038/onc.2008.374. Epub 2008 Oct 6.
5
H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.H3K27me3 在弥漫性中线胶质瘤和上皮性卵巢癌中的作用：相反的表观遗传变化导致相同的不良结局。
Cells. 2022 Oct 26;11(21):3376. doi: 10.3390/cells11213376.
6
Revealing the role of epigenetic and post-translational modulations of autophagy proteins in the regulation of autophagy and cancer: a therapeutic approach.揭示自噬蛋白的表观遗传和翻译后调控在自噬调节及癌症中的作用：一种治疗方法。
Mol Biol Rep. 2023 Dec 8;51(1):3. doi: 10.1007/s11033-023-08961-w.
7
Epigenetics in ovarian cancer.卵巢癌中的表观遗传学。
Semin Cancer Biol. 2018 Aug;51:160-169. doi: 10.1016/j.semcancer.2017.08.003. Epub 2017 Aug 3.
8
Epigenetics in ovarian cancer: premise, properties, and perspectives.卵巢癌中的表观遗传学：前提、特征和展望。
Mol Cancer. 2018 Jul 31;17(1):109. doi: 10.1186/s12943-018-0855-4.
9
Effect of non-enzymatic glycosylation in the epigenetics of cancer.非酶糖基化在癌症表观遗传学中的作用。
Semin Cancer Biol. 2022 Aug;83:543-555. doi: 10.1016/j.semcancer.2020.11.019. Epub 2020 Dec 2.
10
Epigenomics in stress tolerance of plants under the climate change.植物在气候变化下的应激耐受中的表观基因组学。
Mol Biol Rep. 2023 Jul;50(7):6201-6216. doi: 10.1007/s11033-023-08539-6. Epub 2023 Jun 9.
引用本文的文献
1
Potential of histone deacetylase inhibitors for the therapy of ovarian cancer.组蛋白去乙酰化酶抑制剂治疗卵巢癌的潜力。
Front Oncol. 2022 Nov 25;12:1057186. doi: 10.3389/fonc.2022.1057186. eCollection 2022.
2
Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients.卵巢癌患者表观遗传变化引发的顺铂和卡铂耐药性。
Cancer Drug Resist. 2019 Jun 19;2(2):271-296. doi: 10.20517/cdr.2019.010. eCollection 2019.
3
Klotho promoter methylation status and its prognostic value in ovarian cancer.Klotho基因启动子甲基化状态及其在卵巢癌中的预后价值。
Mol Clin Oncol. 2021 Sep;15(3):181. doi: 10.3892/mco.2021.2343. Epub 2021 Jul 3.
4
Circulating Cell-Free DNA Methylation Profiles in the Early Detection of Ovarian Cancer: A Scoping Review of the Literature.循环游离DNA甲基化谱在卵巢癌早期检测中的应用：文献综述
Cancers (Basel). 2021 Feb 17;13(4):838. doi: 10.3390/cancers13040838.
5
Understanding and Targeting Apoptotic Pathways in Ovarian Cancer.了解并靶向卵巢癌中的凋亡途径
Cancers (Basel). 2019 Oct 24;11(11):1631. doi: 10.3390/cancers11111631.
6
Epigenetics in ovarian cancer: premise, properties, and perspectives.卵巢癌中的表观遗传学：前提、特征和展望。
Mol Cancer. 2018 Jul 31;17(1):109. doi: 10.1186/s12943-018-0855-4.
7
Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.卵巢癌新出现的诊断、预后和治疗生物标志物。
Cell Oncol (Dordr). 2017 Apr;40(2):105-118. doi: 10.1007/s13402-016-0309-1. Epub 2016 Dec 15.
8
Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.新型组蛋白去乙酰化酶抑制剂帕比司他（LBH589）对卵巢癌生长的影响
J Ovarian Res. 2016 Sep 15;9(1):58. doi: 10.1186/s13048-016-0267-2.
9
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.上皮性卵巢癌的遗传和表观遗传异质性及其对分子靶向治疗的临床意义。
J Cell Mol Med. 2016 Apr;20(4):581-93. doi: 10.1111/jcmm.12771. Epub 2016 Jan 22.
10
Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation.散发性和林奇综合征相关卵巢癌的表观遗传学分析揭示了组织学特异性的DNA甲基化模式。
Epigenetics. 2014 Dec;9(12):1577-87. doi: 10.4161/15592294.2014.983374.
本文引用的文献
1
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.通过使用低甲基化药物阿扎胞苷逆转铂耐药，在铂耐药或铂难治性上皮性卵巢癌患者中的 1b-2a 期研究。
Cancer. 2011 Apr 15;117(8):1661-9. doi: 10.1002/cncr.25701. Epub 2010 Nov 8.
2
Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences.肿瘤微囊泡中含有逆转录转座子元件和扩增的癌基因序列。
Nat Commun. 2011 Feb 1;2:180. doi: 10.1038/ncomms1180.
3
Serum microRNAs as non-invasive biomarkers for cancer.血清 microRNAs 作为癌症的非侵入性生物标志物。
Mol Cancer. 2010 Nov 26;9:306. doi: 10.1186/1476-4598-9-306.
4
Targeting microRNAs in cancer: rationale, strategies and challenges.靶向癌症中的 microRNAs：原理、策略和挑战。
Nat Rev Drug Discov. 2010 Oct;9(10):775-89. doi: 10.1038/nrd3179.
5
Circulating miRNA signatures: promising prognostic tools for cancer.循环miRNA特征：癌症预后的有前景的工具。
J Clin Oncol. 2010 Oct 10;28(29):e573-4; author reply e575-6. doi: 10.1200/JCO.2010.29.8901. Epub 2010 Aug 9.
6
SGO White Paper on ovarian cancer: etiology, screening and surveillance.SGO 白皮书：卵巢癌的病因、筛查和监测。
Gynecol Oncol. 2010 Oct;119(1):7-17. doi: 10.1016/j.ygyno.2010.06.003. Epub 2010 Aug 7.
7
Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.EZH2 的过表达有助于卵巢癌细胞在体外和体内获得顺铂耐药性。
Cancer Biol Ther. 2010 Oct 15;10(8):788-95. doi: 10.4161/cbt.10.8.12913.
8
Whole blood-derived miRNA profiles as potential new tools for ovarian cancer screening.全血衍生 miRNA 谱作为卵巢癌筛查的潜在新工具。
Br J Cancer. 2010 Aug 24;103(5):693-700. doi: 10.1038/sj.bjc.6605833. Epub 2010 Aug 3.
9
MicroRNAs: synthesis, mechanism, function, and recent clinical trials.微小RNA：合成、机制、功能及近期临床试验
Biochim Biophys Acta. 2010 Nov;1803(11):1231-43. doi: 10.1016/j.bbamcr.2010.06.013. Epub 2010 Jul 7.
10
The importance of imprinting in the human placenta.人类胎盘印迹的重要性。
PLoS Genet. 2010 Jul 1;6(7):e1001015. doi: 10.1371/journal.pgen.1001015.
Zotero 插件